Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02115815 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 246
- Enrollment target
NCT02115815 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 246 participants.
The verdict
NCT02115815, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 246 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the administration of single ascending intramuscular doses of the RSV sF antigen or MEDI7510 will be safe and well tolerated in adults 60 years or older who are healthy or who have stable, chronic underlying medical conditions.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL RSV sF 20 mcg
- BIOLOGICAL MEDI7510 (20 mcg RSV sF)
- BIOLOGICAL RSV sF 50 mcg
- BIOLOGICAL MEDI7510 (50 mcg RSV sF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02115815
The ClinicalTrials.gov registry entry for NCT02115815 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02115815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02115815 about?
NCT02115815 is a clinical study titled "A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults". The purpose of this study is to determine if the administration of single ascending intramuscular doses of the RSV sF antigen or MEDI7510 will be safe and well tolerated in adults 60 years or older who are healthy or who have stable, chronic underlying medical conditions.
What is the current status of trial NCT02115815?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 246 participants. The study started on 2014-04. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02115815?
The interventions under investigation include: Placebo (BIOLOGICAL), RSV sF 20 mcg (BIOLOGICAL), MEDI7510 (20 mcg RSV sF) (BIOLOGICAL), RSV sF 50 mcg (BIOLOGICAL), MEDI7510 (50 mcg RSV sF) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02115815?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.